Cefprozil Tablets

This product is a second-generation cephalosporin drug with a broad-spectrum antibacterial effect. The bactericidal mechanism of this drug is to hinder the synthesis of bacterial cell walls. In vitro tests have shown that cefprozil has a significant effect on Gram-positive aerobic bacteria such as Staphylococcus aureus (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes, and has an inhibitory effect on Enterococcus tenacious, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus Warnei, Streptococcus agalactiae, Streptococcus C, D, F, G groups and Streptococcus viridans. It is ineffective against methicillin-resistant Staphylococcus and Enterococcus faecalis, and is highly sensitive to Gram-negative aerobic bacteria such as Haemophilus influenzae (including beta-lactamase-producing strains) and Moraxella catarrhalis (including beta-lactamase-producing strains); it can inhibit the growth of Citrobacter diversus, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae (including beta-lactamase-producing strains), Proteus mirabilis, Salmonella, Shigella and Vibrio, and has no antibacterial effect on most strains of Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia and Pseudomonas. Cefprozil has a certain inhibitory effect on melanin Bacillus, Clostridium difficile, Clostridium perfringens, Fusobacterium, Streptococcus and Propionibacterium acnes among anaerobic bacteria, and has no antibacterial effect on most strains of Bacillus fragilis.

The main component of this product is cefprozil, of which the cis isomer accounts for about 90%. Its chemical name is (6R,7R)-7-[(R)-2-amino-2-(p-hydroxy-phenyl)acetylamino]-8-oxo-3-propylene-5-thia-1-azabicyclo-(4,2,0)oct-2-ene-2-carboxylic acid monohydrate. Its structural formula is: Molecular formula: C18H19N3O5Stimes;H2O Molecular weight: 407.45

This product is an orange oval film-coated tablet, which appears off-white or light yellow after removing the coating.

For the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infections (1) Pharyngitis/tonsillitis caused by Streptococcus pyogenes. Note: Intramuscular penicillin should usually be used to treat and prevent streptococcal infections (including prevention of rheumatic fever). Although cefuroxime can generally effectively eliminate Streptococcus pyogenes in the nasopharynx, there is currently no data available for the use of cefuroxime to prevent secondary rheumatic fever. (2) Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). 2. Lower respiratory tract infections caused by Streptococcus pneumoniae, Haemophilus influenzae (including

Oral administration, for adults (13 years or older) with upper respiratory tract infection, 0.5g each time, once a day; for lower respiratory tract infection, 0.5g each time, twice a day; for skin or skin soft tissue infection, 0.5g per day, divided into 1 or 2 times, for severe cases, 0.5g each time, twice a day. For upper respiratory tract infection in children aged 2 to 12 years, 7.5mg/kg once according to body weight, twice a day; for skin or skin soft tissue infection, 20mg/kg once according to body weight, once a day. For otitis media in infants from 6 months to 12 years old, 15mg/kg once according to body weight, twice a day; for acute sinusitis, generally 7.5mg/kg once according to body weight, twice a day; for severe cases, 15mg/kg once according to body weight, twice a day. The course of treatment is generally 7 to 14 days, but? Hemolytic chain

1 The adverse reactions of ceftriaxone are similar to those of other oral cephalosporins, mainly gastrointestinal reactions, including diarrhea, nausea, vomiting and abdominal pain. Allergic reactions may also occur, most commonly rashes and urticaria. Allergic reactions are more common in children than in adults, and often occur within a few days after the start of treatment and disappear within a few days after stopping the drug. Other adverse reactions are rare, including: Hepatobiliary system: increased AST (aspartate aminotransferase) and ALT (alanine aminotransferase). Occasionally, alkaline phosphatase and bilirubin are increased. Cholestatic jaundice is rare. Central nervous system: dizziness, hyperactivity, headache, mental tension, insomnia, and occasionally drowsiness. All these reactions are reversible. Blood system: leukopenia, eosinophilia. Kidneys: increased serum urea nitrogen and increased serum creatinine. Others: diaper dermatitis-like

Patients who are allergic to this product or other cephalosporins are contraindicated.

Precautions for children: There is no data on the safety and efficacy of cefoperazone in children under 6 months of age. However, there have been reports of other cephalosporins accumulating in newborns (due to the extended half-life of drugs in children of this age group). Precautions for pregnancy and lactation: A lactating woman who takes 1 gram of cefoperazone orally once can detect a small amount of the drug in breast milk (0.3% of the dose taken). The average concentration over 24 hours is 0.25-3.3 mg/L. Since the effect of cefoperazone on infants is not yet clear, lactating women should be cautious when taking this product. Precautions for the elderly: The average AUC of the elderly (ge; 65 years old) is about 35%-60% higher than that of young adults, and the AUC of women is 15%-20% higher than that of men. However, the differences in the pharmacokinetics of cefoperazone between age and gender are not sufficient to indicate the need for dose adjustment.

Nephrotoxicity has been reported with the combined use of aminoglycosides and cephalosporins. Coadministration with probenecid can double the AUC of cefprozil. Drug/Laboratory Test Interactions Cephalosporin antibiotics can cause false-positive reactions in urine glucose reduction tests [Benedict or Feling's reagents or copper sulfate tablets (Clinitestacirc; tablets)], but not in urine glucose enzymatic tests (such as Tes-Tapeacirc; urine glucose test strips). This class of drugs can cause false-negative blood glucose ferrocyanide reactions. Cefprozil in the blood does not interfere with the determination of creatinine in the blood or urine by the alkaline picrate method.

Protect from light, seal tightly, and store in a cool and dry place.

0.25 g

24 months.

Nanjing Yewin Pharmaceutical Co., Ltd.

• Founded in:

  2002-12-24

• Address:

  No. 18, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192745358509L

• Registered Funds:

  15 million yuan

• Website:

  Log in to view

• Email:

  Log in to view